New Pharmaceutical Company To Target Alzheimer's Disease A team of world-renowned scientists announced the launch of Archer Pharmaceuticals, Inc., a new company that will use modern technologies for the identification of novel treatments for Alzheimer's disease. Archer Pharmaceuticals, Inc., led by Chief Executive Officer Michael Mullan, M.B.B.S., Ph.D. and Chief Technical Officer Fiona Crawford, Ph.D.
Source: www.medicalnewstoday.comAccess Pharmaceuticals Presents ProLindac(TM) Data At The AACR-NCI-EORTC Symposium 2008 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced that three posters describing significant recent results of the company's proprietary polymer DACH platinum prodrug, ProLindac, in clinical and preclinical studies are being presented this week at a major international oncology conference held in Geneva, Switzerland.
Source: www.medicalnewstoday.comSelf-Assembling Nano-Fiber Gel Delivers High Concentrations Of Clinically Approved Drugs Two teams of scientists from Harvard-MIT Division of
Health Science and Technology (HST) at Brigham and Women's Hospital have developed a new self-assembling hydrogel drug delivery system that is biocompatible, efficient at drug release, and easy to tailor. Importantly, these structures can deliver clinically approved
drugs in high concentrations without requiring carriers for the drug or generating toxic components, a problem with hydrogel systems until now.
Source: www.medicalnewstoday.comEuropean Researchers Harness Unique Properties Of Boron To Develop New Drugs And Diagnostics Researchers are on the verge of unleashing the power of the element boron in a new generation of
drugs and therapies, as decades of research begins to bear fruit. Boron has to date far been one of biology's best kept secrets, but is now attracting fast growing research interest and investment from the pharmaceutical industry in the quest for novel
drugs to tackle cancer and infectious diseases, potentially overcoming limitations and side effects of current products.
Source: www.medicalnewstoday.comClinical Update - Debio 9902 SR (ZT-1) For Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study Under IND Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announced that the first
healthy elderly subjects have been randomised in a clinical bioequivalence bridging study, conducted in the United States under IND (Investigational New Drug).
Source: www.medicalnewstoday.comHow Safe Are Biological Medicines? According to an article published in the October 22/29 issue of JAMA, about 25% of biological medicinal products that United States and European authorities have approved since 1995 have had at least one regulatory action issued due to safety within 10 years after approval. Around 11% of these antibody, enzyme, and insulin products have even received "black box" warnings that indicate the possibility of serious side effects.
Source: www.medicalnewstoday.comGlycotex Reports First Patient Enrollment In Phase IIb Study Of Lead Product Candidate GLYC-101 For Wound Healing Glycotex, Inc. announced enrollment of the first patient in a Phase IIb study evaluating the effect of GLYC-101 on wound closure and cosmetic outcomes in cosmetic surgery patients undergoing carbon dioxide laser skin resurfacing on the lower eyelid area. A previous Phase II Pilot Study, investigating clinical outcomes and safety parameters of GLYC-101 at two doses compared to placebo was completed in April 2008.
Source: www.medicalnewstoday.comMore People Applying For Drug-Assistance Programs Amid Economic Downturn As the "slowing economy swells the ranks of the unemployed -- and uninsured -- more people are getting help from
prescription drug assistance programs normally aimed at providing medications to the poorest Americans," the Wall Street Journal reports. The programs, sponsored by pharmaceutical companies, provide consumers with billions of dollars worth of no-cost
drugs every year.
Source: www.medicalnewstoday.comSouthampton Hospital Pharmacists Rewarded For Scheme That Relieves Hard-pressed Doctors' Workloads, UK Pharmacists and nurses at Southampton's teaching hospitals have been recognised nationally for their progression of an innovative scheme designed to relieve the workloads of hard-pressed doctors. In recognition of their system of prescribing
medicine, Southampton University Hospitals Trust's pharmacy department and nutrition support team will collect the prestigious GlaxoSmithKline Advanced Practitioner Award 2008 at a ceremony in Leicestershire on November 21.
Source: www.medicalnewstoday.com
# posted by Network @ 12:00 PM
